BPC-157 + TB-500 Stack vs Oxytocin
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
BPC-157 + TB-500 Stack
The most widely researched peptide stack for tissue repair, combining BPC-157 (angiogenesis and growth factor upregulation) with TB-500 (actin regulation and cell migration). The two compounds address complementary and non-overlapping stages of the healing cascade, producing synergistic effects in tendon, ligament, muscle, and gut injury research models.
Full profileOxytocin
Endogenous 9-amino acid neuropeptide produced in the hypothalamus with roles in social bonding, trust, and childbirth. Research applications span wound healing, anti-inflammatory effects, sexual function, anxiety reduction, and autonomic nervous system regulation. Intranasal administration crosses the blood-brain barrier and is the primary research route for behavioral and neurological applications.
Full profile| BPC-157 + TB-500 Stack | Oxytocin | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Wolverine Stack, BPC TB500 combination, healing stack, BPC-157 TB-500 | OT, Pitocin, Syntocinon, trust hormone, bonding peptide |
| Evidence | Research-stage | Research-stage |
| Dosing range | BPC-157 250mcg + TB-500 2.5mg–BPC-157 750mcg + TB-500 7.5mg varies by component, 2–3x per week | 10–20IU–100–160IU IU, Intranasal 30–60 minutes pre-activity; 1–2x daily for wound healing or anti-inflammatory protocols |
| Administration | Subcutaneous injection, Intramuscular injection | Intranasal spray, Subcutaneous injection, Intravenous (clinical) |
| Key side effects | BPC-157: nausea (rare), dizziness, lightheadedness, TB-500: fatigue, headache, injection site reactions, No documented combination-specific adverse effects, Theoretical oncological considerations (angiogenesis stimulation) — relevant in cancer history | Nausea, Headache, Transient hypotension, Hyponatremia (high IV doses — water retention effect) |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: BPC-157 + TB-500 Stack — Subcutaneous injection, Intramuscular injection; Oxytocin — Intranasal spray, Subcutaneous injection, Intravenous (clinical).
- Dosing units differ: BPC-157 + TB-500 Stack is dosed in varies by component, Oxytocin in IU — they operate at different scales.
- Frequency: BPC-157 + TB-500 Stack is typically 2–3x per week; Oxytocin is Intranasal 30–60 minutes pre-activity; 1–2x daily for wound healing or anti-inflammatory protocols.
How each works
BPC-157 + TB-500 Stack
BPC-157 and TB-500 work through entirely non-overlapping mechanisms and have been combined in numerous community protocols for injury recovery. BPC-157 drives angiogenesis and growth factor receptor expression; TB-500 regulates actin polymerization and cell migration into the injury site. No documented negative interactions exist — the combination is considered synergistic in the healing research community based on the complementary biology of each compound.
Oxytocin
Oxytocin binds oxytocin receptors (OTR) throughout the brain and periphery, producing prosocial, anxiolytic, and anti-inflammatory effects. The landmark 2005 Kosfeld et al. Nature study demonstrated that intranasal oxytocin increased trust in humans in economic game paradigms. Peripheral effects include acceleration of wound healing, modulation of inflammatory cytokines, and parasympathetic nervous system activation.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.